LGALS3 and metabolic dysfunction-associated steatohepatitis: Simtuzumab (lysyl oxidase like 2 antagonist), which targets ECM cross-linking, had no effect in NASH-, HCV/HIV-, or primary sclerosing cholangitis-related CLD due to redundant mechanisms contributing to tissue stiffening in more advanced stages of the disease.[98], [99], [100] Similarly, inhibition of galectin-3 (a pro-inflammatory and profibrotic factor) has shown basically no effect in NASH-related CLD.101